Onco-Carbide
Category
Onco-Carbide Brand names, Onco-Carbide Analogs
Onco-Carbide Brand Names Mixture
Onco-Carbide Chemical_Formula
CH4N2O2
Onco-Carbide RX_link
http://www.rxlist.com/cgi/generic2/hydroxyurea.htm
Onco-Carbide fda sheet
Onco-Carbide msds (material safety sheet)
Onco-Carbide Synthesis Reference
No information avaliable
Onco-Carbide Molecular Weight
76.0547 g/mol
Onco-Carbide Melting Point
142-146 oC
Onco-Carbide H2O Solubility
1E+006 mg/L
Onco-Carbide State
Solid
Onco-Carbide LogP
-1.432
Onco-Carbide Dosage Forms
Capsule
Onco-Carbide Indication
For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Onco-Carbide Pharmacology
Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro. In vivo Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction.
Onco-Carbide Absorption
Well absorbed from the gastrointestinal tract.
Onco-Carbide side effects and Toxicity
Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg
Onco-Carbide Patient Information
HYDREA is a medication that must be handled with care. People who are not taking HYDREA should not be
exposed to it. If the powder from the capsule is spilled, it should be wiped up immediately with a damp disposable
towel and discarded in a closed container, such as a plastic bag. The medication should be kept away from children
and pets.
Onco-Carbide Organisms Affected
Humans and other mammals
